ArticleBMC pediatrics2025
Endoscopic retrograde cholangiopancreatography treatment for biliary dilatation in pediatric patients: a retrospective multicenter study.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe main treatments for biliary dilatation (BD) are surgical resection and choledochojejunostomy. However, various factors lead to the postponement of early surgical intervention in pediatric BD patients. This study aimed to analyze the effectiveness and limitations of endoscopic retrograde cholangiopancreatography (ERCP) in BD pediatric patients.
methodsData on patients with BD treated at two centers from June 2018 to June 2022 were retrospectively collected. Patients were categorized into five groups according to Todani classification. Clinical features, ERCP processes, ERCP-related complications, ERCP effectiveness and its limitations were reviewed.
resultsA cohort of 77 symptomatic BD patients was evaluated, with pancreaticobiliary malformation (PBM) identified in 68.8% of cases. These patients underwent 142 hospitalizations, including 96 involving ERCP and 46 without ERCP. ERCP was performed in 74.0% (57/77) of BD patients, with a median follow-up of 26 months (range: 2-48 months), achieving an effectiveness rate of 75.4%. ERCP-related complications included post-ERCP pancreatitis (20.8%), postoperative infections (6.3%), and bleeding (2.1%). All complications were mild and managed conservatively. Further stratified analysis revealed that patients under 36 months of age at onset (P = 0.001) and those with elevated liver enzymes (P = 0.049) did not respond well to ERCP. The proportion of jaundice (P = 0.006) and biliary obstruction (P = 0.013) was significantly higher in the group with an onset age of ≤ 36 months compared to the group with an onset age > 36 months.
conclusionsERCP is suitable for BD pediatric patients with mild and acceptable complications. Careful consideration is required when deciding to perform the procedure, as therapeutic outcomes are limited in patients with an onset age under 36 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.